ArticleJournal of cancer research and clinical oncology2009
Substantially reduced expression of PIAS1 is associated with colon cancer development.
Article in Journal of cancer research and clinical oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- Integrative analysis revealed a correlation of PIAS family genes expression with prognosis, immunomodulation and chemotherapy.European journal of medical research · 2024Article
- The emerging roles of SUMOylation in the tumor microenvironment and therapeutic implications.Experimental hematology & oncology · 2023Review
- The Cajal body marker protein coilin is SUMOylated and possesses SUMO E3 ligase-like activity.Frontiers in RNA research · 2023Article
- Cancer-Associated Dysregulation of Sumo Regulators: Proteases and Ligases.International journal of molecular sciences · 2022Review
- PD-L1 upregulation is associated with activation of the DNA double-strand break repair pathway in patients with colitic cancer.Scientific reports · 2021Article
- The Function of SUMOylation and Its Role in the Development of Cancer Cells under Stress Conditions: A Systematic Review.Stem cells international · 2020Review
- Developing Practical Therapeutic Strategies that Target Protein SUMOylation.Current drug targets · 2019Review
- PIAS1 is not suitable as a urothelial carcinoma biomarker protein and pharmacological target.PloS one · 2019Article
- Protein SUMOylation modification and its associations with disease.Open biology · 2017Review
- SUMO and the robustness of cancer.Nature reviews. Cancer · 2017Review
- Identification of the SUMO E3 ligase PIAS1 as a potential survival biomarker in breast cancer.PloS one · 2017Article
- PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells.Oncotarget · 2014Article
- QUANTITATIVE MORPHOLOGICAL AND MOLECULAR PATHOLOGY OF THE HUMAN THYMUS CORRELATE WITH INFANT CAUSE OF DEATH.Technology and innovation · 2014Article
- PIAS1-modulated Smad2/4 complex activation is involved in zinc-induced cancer cell apoptosis.Cell death & disease · 2013Article
- Integrated analyses of genome-wide DNA occupancy and expression profiling identify key genes and pathways involved in cellular transformation by a Marek's disease virus oncoprotein, Meq.Journal of virology · 2013Article
- A systems biology approach to the global analysis of transcription factors in colorectal cancer.BMC cancer · 2012Article
- Coactivation of SF-1-mediated transcription of steroidogenic enzymes by Ubc9 and PIAS1.Endocrinology · 2011Article
- A signature inferred from Drosophila mitotic genes predicts survival of breast cancer patients.PloS one · 2011Article
- NF-κB and cancer: a paradigm of Yin-Yang.American journal of cancer researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeProtein inhibitors of activated STATs (PIAS) regulate the interferon-gamma (IFN-gamma) signaling pathway, which has numerous effects on tumor development and tumor cell biology. PIAS's also regulate STAT family members not directly involved in IFN-gamma signaling. This project was designed to assess PIAS1 expression in colon cancer.
methodsTo determine whether PIAS1, one of the PIAS family members, or IFN-gamma signaling pathway components could be used to stratify colon tumors, we stained tissue microarrays for PIAS1, interferon regulatory factor-1 (IRF-1) and STAT1alpha.
resultsPIAS1 staining of the colon cancer tissue microarrays indicated a strong correlation of normal colon cells, and adenomas, with high expression of both PIAS1 and IRF-1.
conclusionThe PIAS1 results in particular may represent a basis for new approaches for efficiently distinguishing adenomas from colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.